Cytori Reports Encouraging Results From Breast Augmentation Study
Posted on: Monday, 19 May 2008, 09:01 CDT
Cytori Therapeutics has reported promising results from an independent study in Japan using adipose-derived stem and regenerative cells for breast augmentation.
Early results on the first three patients from this investigator-initiated study showed the increase in breast volume was maintained at three months and that the tissue remained soft and natural.
At three months, breast circumference in the first three patients remained stable at an average increase of four centimeters, which is equivalent to a 1.6 cup size increase. An average net volume of 160mL (less saline) of cell enhanced fat tissue was transplanted into each breast of each patient. The procedure to date has been found safe with no report of any adverse events. Patient follow-up is ongoing in this 20 patient investigator-initiated study. Nine-month results will be reported in early 2009, shortly after the last patient follow-up.
The study is using a procedure whereby a woman's fat tissue is enriched with her own adipose derived stem and regenerative cells to create a natural filler. This technique is referred to as cell-enhanced augmentation. The cells in the study were made available at the time of surgery using the Celution 800 System from Cytori Therapeutics. Further results from the study will be available following a nine month assessment of the primary endpoints of cosmetic improvement and volume retention.
Source: Datamonitor
Related Articles
- Early-Stage, HER2-Positive Breast Cancer Patients At Increased Risk Of Recurrence
- Generex Biotechnology Phase I Trial Results for Novel Immunotherapy Vaccine in Breast Cancer Patients Presented At ASCO
- N.L. Breast Cancer Patient Told This Week Tissue Sample Retested
- Study: Gene Mutation More Prevalent in Hispanic, Young Black Breast Cancer Patients
- Introgen Announces Positive Phase 2 Clinical Trial Results With INGN 225 Immunotherapy in Patients With Small Cell Lung Cancer
- Caritas St. Elizabeth's Medical Center's Study Finds Injecting Patient's Own Stem Cells into the Heart to Treat Severe Coronary Artery Disease is Well Tolerated
- Pluristem Announces Breakthrough in Bone Marrow Transplants: Engrafted Cells Increase 2-4 Times in Preclinical Study
- Older Breast Cancer Patient Care Studied
- 'Real Life' Study Clarifies Risk of Recurrence for High-Risk Breast Cancer Patients
- Study of Breast Cancer Patients Showed Regimen Including EMEND-R- -Aprepitant- Prevented Nausea and Vomiting After Chemotherapy in More Patients Than a Standard Regimen
 |
 |
User Comments (0)
RSS Feeds